دورية أكاديمية
أعرض في EDS

Critical evaluation of different available guidelines for late-onset hypogonadism.

التفاصيل البيبلوغرافية
العنوان: Critical evaluation of different available guidelines for late-onset hypogonadism.
المؤلفون: Giagulli VA; Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy.; Outpatients Clinic of Endocrinology and Metabolic Disease, Conversano Hospital, Bari, Italy., Castellana M; National Institute of Gastroenterology 'Saverio de Bellis', Research Hospital, Bari, Italy., Lisco G; Hospital Unit of Endocrinology, Perrino Hospital, Brindisi, Italy., Triggiani V; Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy.
المصدر: Andrology [Andrology] 2020 Nov; Vol. 8 (6), pp. 1628-1641. Date of Electronic Publication: 2020 Jul 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101585129 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-2927 (Electronic) Linking ISSN: 20472919 NLM ISO Abbreviation: Andrology Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Wiley-Blackwell, 2013-
مواضيع طبية MeSH: Endocrinology/*standards , Eunuchism/*drug therapy , Hormone Replacement Therapy/*standards , Practice Guidelines as Topic/*standards , Testosterone/*therapeutic use, Adult ; Age of Onset ; Aged ; Biomarkers/blood ; Consensus ; Eunuchism/blood ; Eunuchism/diagnosis ; Eunuchism/physiopathology ; Evidence-Based Medicine/standards ; Hormone Replacement Therapy/adverse effects ; Humans ; Middle Aged ; Risk Factors ; Testosterone/adverse effects ; Testosterone/blood ; Testosterone/deficiency ; Treatment Outcome
مستخلص: Background: Late-onset hypogonadism (LOH) is a syndrome characterized by clinical and biochemical evidence of low testosterone levels with advancing age. In recent years, several guidelines, position statements and other recommendations have become available. It is unclear whether similar indications are reported in these documents.
Objective: To review similarities and differences among available documents on the management of hypogonadism, with a special focus on LOH.
Materials and Methods: PubMed, Google and international societies websites were searched on March 2020 for documents published in the last 10 years on the management of hypogonadism and LOH.
Results: Nine documents were found, each developed by: (a) the American Urological Association; (b) the British Society for Sexual Medicine; (c) the Canadian Medical Association; (d) the Endocrine Society; (e) the Endocrine Society of Australia; (f) the European Academy of Andrology; (g) the European Association of Urology; (h) the International Consultation for Sexual Medicine; and (i) the International Society for the Study of Aging Male.
Discussion: Despite similar principles, differences were found both for the diagnostic workup and follow-up. Particularly, discrepancies were reported both for total and free testosterone levels for diagnosis and for total testosterone for monitoring.
Conclusion: Available documents differ in terms of specific recommendations for the management of hypogonadism and LOH. Given the relevant clinical implications of adequate management of these disorders, future guidelines should report more consistent measures to be adopted in clinical practice.
(© 2020 American Society of Andrology and European Academy of Andrology.)
References: Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26(6):833-876.
Kaufman JM, Lapauw B, Mahmoud A, T'Sjoen G, Huhtaniemi IT. Aging and the Male Reproductive System. Endocr Rev. 2019;40(4):906-972.
Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516.
Barbonetti A, D'Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020 [Epub ahead of print]; https://doi.org/10.1111/andr.12774.
Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020;17(3):447-460.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
Hackett G, Kirby M, Edwards D, et al. British society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017;14(12):1504-1523.
Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ. 2015;187(18):1369-1377.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust. 2016;205(4):173-178.
Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Med J Aust. 2016;205(5):228-231.
Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020 [Epub ahead of print];https://doi.org/10.1111/andr.12770.
Salonia A, Bettocchi C, Carvalho J, et al.EAU guidelines on Sexual and Reproductive Health. Available at https://uroweb.org/guideline/sexual-and-reproductive-health/.
Morgentaler A, Traish A, Hackett G, Jones TH, Ramasamy R. Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 international consultation for sexual medicine. Sex Med Rev. 2019;7(4):636-649.
Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5-15.
Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95(4):1810-1818.
Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067-1075.
World Health Organization. World report on Ageing and Health, 2015. https://apps.who.int/iris/bitstream/handle/10665/186463/9789240694811_eng.pdf;jsessionid=82CA7E613E123FC22EDD5BF4480DE1DF?sequence=1. Accessed March 1, 2020.
Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369-386.
Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135.
Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-4247.
Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343.
Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new ‘aging males’ symptoms' rating scale. Aging Male. 1999;2:105-114.
Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49(9):1239-1242.
Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000;53(6):703-711.
Corona G, Mannucci E, Petrone L, et al. ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med. 2006;3(4):706-715.
Trost LW, Mulhall JP. Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials. J Sex Med. 2016;13(7):1029-1046.
Giagulli VA, Vermeulen A. Leydig cell function in infertile men with idiopathic oligospermic infertility. J Clin Endocrinol Metab. 1988;66(1):62-67.
Travison TG, Vesper HW, Orwoll E, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173.
Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods [published correction appears in Steroids. Steroids. 2009;74(6):498-503.
Huhtaniemi IT, Tajar A, Lee DM, et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012;166(6):983-991.
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672.
Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405-413.
Morris PD, Malkin CJ, Channer KS, Jones TH. A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol. 2004;151(2):241-249.
Antonio L, Wu FCW, O'Neill TW, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101(7):2647-2657.
Fiers T, Wu F, Moghetti P, Vanderschueren D, Lapauw B, Kaufman JM. Reassessing free-testosterone calculation by liquid chromatography-tandem mass spectrometry direct equilibrium dialysis. J Clin Endocrinol Metab. 2018;103(6):2167-2174.
Rastrelli G, Corona G, Maggi M. Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl. 2020;22(3):265-273.
Ruhayel Y, Malm G, Haugen TB, et al. Seasonal variation in serum concentrations of reproductive hormones and urinary excretion of 6-sulfatoxymelatonin in men living north and south of the Arctic Circle: a longitudinal study. Clin Endocrinol (Oxf). 2007;67(1):85-92.
Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl. 1989;10(5):366-371.
Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf). 2007;67(6):853-862.
Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907-913.
Orwoll ES, Nielson CM, Labrie F, et al. Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab. 2010;95(10):E151-E160.
Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab. 2007;92(9):3604-3610.
Ring HZ, Lessov CN, Reed T, et al. Heritability of plasma sex hormones and hormone binding globulin in adult male twins. J Clin Endocrinol Metab. 2005;90(6):3653-3658.
Terrier JE, Isidori AM. How food intakes modify testosterone level. J Sex Med. 2016;13(9):1292-1296.
Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12(1):5-12.
van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85(9):3276-3282.
Guay A, Miller MG, McWhirter CL. Does early morning versus late morning draw time influence apparent testosterone concentration in men aged > or =45 years? Data from the Hypogonadism In Males study. Int J Impot Res. 2008;20(2):162-167.
Gagliano-Jucá T, Li Z, Pencina KM, et al. Oral glucose load and mixed meal feeding lowers testosterone levels in healthy eugonadal men. Endocrine. 2019;63(1):149-156.
Caronia LM, Dwyer AA, Hayden D, Amati F, Pitteloud N, Hayes FJ. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf). 2013;78(2):291-296.
Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014;11(3):362-375.
Giagulli VA, Triggiani V, Carbone MD, et al. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism. J Sex Med. 2011;8(12):3471-3478.
Giagulli VA, Guastamacchia E, Licchelli B, Triggiani V. Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence. Recent Pat Endocr Metab Immune Drug Discov. 2016;10(1):22-30.
Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76(1):31-40.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.
Giagulli VA, Castellana M, Pelusi C, Triggiani V. Androgens, body composition, and their metabolism based on sex. Front Horm Res. 2019;53:18-32.
Corona G, Giagulli VA, Maseroli E, et al. THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-R116.
Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967-981.
O'Donnell AB, Travison TG, Harris SS, Tenover JL, McKinlay JB. Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2006;91(2):425-431.
Maggio M, Lauretani F, Ceda GP. Sex hormones and sarcopenia in older persons. Curr Opin Clin Nutr Metab Care. 2013;16(1):3-14.
Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100(8):2956-2962.
Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272-285.
Zhang J, Yang B, Xiao W, Li X, Li H. Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol. 2018;36(8):1315-1326.
Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835-842.
Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
Cunningham GR, Ellenberg SS, Bhasin S, et al. Prostate-specific antigen levels during testosterone treatment of hypogonadal older men: data from a controlled trial. J Clin Endocrinol Metab. 2019;104(12):6238-6246.
Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;7(11):e015284.
Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 3 March 2015. Available at: https://www.fda.gov/media/91048/download.
Government of Canada. Summary Safety Review - Testosterone Replacement Products - Health Canada. 15 July 2014. Available at: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?linkID=SSR00058.
Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018;15(6):820-838.
Killick R, Wang D, Hoyos CM, Yee BJ, Grunstein RR, Liu PY. The effects of testosterone on ventilatory responses in men with obstructive sleep apnea: a randomised, placebo-controlled trial. J Sleep Res. 2013;22(3):331-336.
Hoyos CM, Killick R, Yee BJ, Grunstein RR, Liu PY. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2012;77(4):599-607.
Giagulli VA, Guastamacchia E, De Pergola G, Iacoviello M, Triggiani V. Testosterone deficiency in male: a risk factor for heart failure. Endocr Metab Immune Disord Drug Targets. 2013;13(1):92-99.
Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260-1271.
Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500-1511.
Corona G, Rastrelli G, Morelli A, et al. Treatment of functional hypogonadism besides pharmacological substitution. World J Men's Health. 2020;38(3):256.
Cignarelli A, Castellana M, Castellana G, et al. Effects of CPAP on testosterone levels in patients with obstructive sleep apnea: a meta-analysis study. Front Endocrinol (Lausanne). 2019;10:551.
Giagulli VA, Castellana M, Murro I, et al. The role of diet and weight loss in improving secondary hypogonadism in men with obesity with or without type 2 diabetes mellitus. Nutrients. 2019;11(12):2975.
Morelli A, Filippi S, Comeglio P, et al. Physical activity counteracts metabolic syndrome-induced hypogonadotropic hypogonadism and erectile dysfunction in the rabbit. Am J Physiol Endocrinol Metab. 2019;316(3):E519-E535.
Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39(2):79-132.
Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010;7(1 Pt 1):156-165.
Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care. 2018;41(7):1516-1525.
Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab. 1994;79(4):997-1000.
Molina-Vega M, Asenjo-Plaza M, García-Ruiz MC, et al. Cross-sectional, primary care-based study of the prevalence of hypoandrogenemia in nondiabetic young men with obesity. Obesity (Silver Spring). 2019;27(10):1584-1590.
Costanzo PR, Suárez SM, Scaglia HE, Zylbersztein C, Litwak LE, Knoblovits P. Evaluation of the hypothalamic-pituitary-gonadal axis in eugonadal men with type 2 diabetes mellitus. Andrology. 2014;2(1):117-124.
López-Alvarenga JC, Zariñán T, Olivares A, González-Barranco J, Veldhuis JD, Ulloa-Aguirre A. Poorly controlled type I diabetes mellitus in young men selectively suppresses luteinizing hormone secretory burst mass. J Clin Endocrinol Metab. 2002;87(12):5507-5515.
Giagulli VA, Castellana M, Carbone MD, et al. Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology. 2020;8(3):654-662.
Pelusi C, Giagulli VA, Baccini M, et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. PLoS One. 2017;12(9):e0183369.
Krzastek SC, Smith RP. Non-testosterone management of male hypogonadism: an examination of the existing literature. Transl Androl Urol. 2020;9(Suppl 2):S160-S170.
Rastrelli G, Maggi M, Corona G. Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol. 2018;11(4):439-458.
فهرسة مساهمة: Keywords: ageing; guidelines; hypogonadism; late-onset hypogonadism; review
المشرفين على المادة: 0 (Biomarkers)
3XMK78S47O (Testosterone)
تواريخ الأحداث: Date Created: 20200628 Date Completed: 20211011 Latest Revision: 20211011
رمز التحديث: 20231215
DOI: 10.1111/andr.12850
PMID: 32593233
قاعدة البيانات: MEDLINE
الوصف
تدمد:2047-2927
DOI:10.1111/andr.12850